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The recognition of post-translational modiﬁcations by various
protein domains represents an important mechanism for cellular
regulation. The ability of members of the Royal Family of proteins,
including the Tudor domain subfamily, in binding methylated pro-
tein substrate has been well documented (reviewed in [1–6]).
However, much remains to be elucidated with regard to precise
mechanisms by which such interactions inﬂuence the processes
of transcription, translation and RNA splicing.
The tails of histones H3, H4, H2A and H2B make contacts with
the poly-anionic backbone of core nucleosomal DNA, thereby
contributing to nucleosome stability and in turn the high order
chromatin structure [7]. The regulation of chromatin structure
and the resultant transcriptional activity within a given region of
chromatin is inﬂuenced by the post-translational modiﬁcations of
histone tails [8–10]. In particular, histones H3 and H4 are subject
to numerous post-translational modiﬁcations at multiple sites,
including the mono-, di- and tri-methylation of lysine residues
distributed along the tails. Catalyzed by large complex-forming
methyltransferases, the deposition of such methyl marks has beenchemical Societies. Published by E
logy, University of Toronto,associated with states of active or repressed transcription and the
recognition of such marks appears important in targeting large
multicomponent protein complexes to their respective sites [11].
The PHD ﬁnger protein 20 (PHF20/GLEA2/HCA58) is a compo-
nent of some mixed-lineage leukemia (MLL) methyltransferase
complexes with the core components MLL, ASH2L, WDR5 and
RBBP5 [12]. Clinically, antibodies against PHF20 are present in sera
from patients with hepatocellular carcinoma, glioblastoma and
childhood medulloblastula [13–15]. It is one of few immunogenic
antigens identiﬁed via ELISA for gliomas and exhibits the most fre-
quent seroreactive response from glioma patients [15].
PHF20 comprises two N-terminal Tudor domains, a central
C2H2-link zinc ﬁnger domain and a C-terminal zinc-binding PHD
domain (Fig. 1). Although little is known about its cellular role,
the domain organization of PHF20 and the association of PHF20
with MLL core complexes suggest it to function as a transcription
factor. Previous studies have indicated that the second Tudor
domain is capable of binding methylated resides on histone tails
[16], while no such function has been ascribed to the ﬁrst Tudor
domain. In this work, we report the crystal structures of the two
N-terminal Tudor domains of PHF20. We show that both Tudor
domains possess novel structural features, which may underlie
their respective cellular functions. We have also explored the
potential interactions of the respective domains with various
histone-derived peptides by ﬂuorescence polarization assays andlsevier B.V. All rights reserved.
Fig. 1. PHF20 is a multidomain protein with tandem Tudor domains. (A) The domain organization of PHF20. (B) The sequence alignment of the individual PHF20 Tudor
domains (Tud1 and Tud2) with other Tudor domain-containing proteins. Residues comprising the respective aromatic cages are indicated in underlined bold font.
Table 1
Data collection and reﬁnement statistics.
PHF20
(residues 1–
81)
PHF20
(residues 83–
150)
PDB code 3Q1J 3QII
X-ray source Rigaku FR-E CLS beamline
08ID
X-ray wavelength (Å) 1.5418 0.9791
Detector Rigaku R-Axis
4-HTC
MAR 300 CCD
Oscillation range 360  0.5 180  1
Space group C2 P43212
a, b, c (Å) 60.50, 41.06,
28.63
48.68, 48.68,
96.27
a, b, c () 90, 110.33, 90 90, 90, 90
Resolution (outer shell, Å) 20.00–2.35
(2.43–2.35)
50.00–2.30
(2.34–2.30)
Unique observed HKLs 2828 (288) 5606 (237)
Completeness (%) 99.8 (100.0) 99.2 (86.8)
Friedel Redundancy 3.4 (3.3) 12.3 (6.4)
Rsym 0.100 (0.654) 0.069 (0.318)
<I>/<r> 18.4 (2.2) 46.3 (3.6)
MR model PDB code 2RHU 2O4X
Post-MR density modiﬁcation DM, RESOLVE DM
Final model reﬁnement AUTOBUSTER REFMAC [26]
Reﬁnement resolution (Å) 19.08–2.35 30.00–2.30
Number of reﬂections (of which free set) 2804 (131) 5533 (266)
Rwork/Rfree 0.205/0.260 0.235/0.268
Number of atoms/mean B factor (Å2) 557/43.5 431/46.2
Protein 552/43.5 421/46.3
Water 5/41.1 10/42.3
RMSD bond lengths (Å)/angles () 0.010/1.0 0.016/1.4
PROCHECK
Ramachandran residues in most
favored regions/total
51/56 46/47
Additional allowed 5/56 1/47
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ence for dimethylated histones substrates.
2. Materials and methods
2.1. Expression, puriﬁcation and crystallization of PHF20 Tudor
domains
Two fragments of human PHF20 (residues 1–81 and 83–150)
covering the ﬁrst and second Tudor domain, respectively, were sub-
cloned into a pET-28a-MHL vector. The recombinant protein was
over-expressed at 18 C as an N-terminal His6-tagged protein in
Escherichia coli BL21 (DE3) Codon plus RIL (Strategene). Following
puriﬁcation via Ni–NTA column and size exclusion chromatography
(Superdex 75, GE Healthcare), each protein was concentrated to
20 mg/ml in 20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM DTT.
Puriﬁed PHF20 Tudor domain 1 (residues 1–81) was crystallized
in a buffer containing 25% PEG 3350, 0.2 M ammonium acetate,
0.1 M bis–tris pH 5.5 using the sitting drop vapor diffusion method
at 18 C. The crystal appeared overnight. Prior to freezing, the crys-
tals were soaked in a drop containing mother liquor plus 10–15%
glycerol.
Puriﬁed PHF20 Tudor domain 2 (83–150) was crystallized in
25% PEG 8000, 0.2 M sodium chloride, 0.1 M Tris, pH 8.5 using sit-
ting drop vapor diffusion at 18 C. The crystal appeared overnight.
Prior to freezing, the crystals were soaked in a drop containing
mother liquor plus 10–15% glycerol.
2.2. Fluorescence polarization binding assay
All peptides used for ﬂuorescence polarization measurements
were synthesized N-terminally labeled with ﬂuorescein and puri-
ﬁed by Tufts University Core Services. The buffer used in the ﬂuo-
rescence polarization assay was 20 mM Tris pH7.5, 150 mM NaCl,
1 mM DTT and 0.01% Triton X-100. The protein concentration
was varied from 0.97 to 1000 lM and the peptide concentration
was 40 nM. An excitation wavelength of 485 nm and an emission
wavelength of 528 nm were used. The data were measured at
25 C and corrected for background by subtracting the free-labeled
peptide background. The data were collected by the Synergy 2
(BioTec, USA) ﬂuorescence polarization program and were ﬁt to a
hyperbolic function for a single binding site using Origin 7 (Micro-
Cal, Inc.).
2.3. Structure determination and reﬁnement
Diffraction data were reduced using the HKL2000 suite [17]. Ini-
tial molecular replacements (MR) was performed with the program
PHASER [18]. The search models were modiﬁed by alignment of
the target sequence using the FFAS03 server [19] and SCWRL
[20]. For PHF20.83-150, automated model tracing was performed
using both BUCCANEER [21]and ARP/wARP [22]. For PHF20.4-69,building of the ﬁnal model was initiated from the coordinates of
PDB [23] entry 2EQM, which were placed into a RESOLVE [24]-
modiﬁed electron density map by the program MOLREP [25]. For
both structures, intermediate model reﬁnement and rebuilding
were performed with REFMAC [26] and COOT [27], respectively.
Model geometry was monitored on the MOLPROBITY server
[28,29]. Model depositions in the PDB were prepared with PDB_EX-
TRACT [30].
3. Results
3.1. The N-terminal Tud1 domain has an atypical aromatic age and
occluded secondary binding site
The crystal structure of the ﬁrst Tudor domain of PHF20 (resi-
dues 1–81, referred to as Tud1 hereafter) was determined at
2.35 Å by molecular replacement (Table 1). PHF20-Tud1 comprises
a typical Tudor domain with ﬁve b-sheets arranged antiparallel in
Fig. 2. The crystal structure of Tud1 from PHF20. Tud1 domain interacts with the extended N-terminal tail (shown in gray) of PHF20. This N-terminal tail and it binding site is
depicted in the top insert. Excellent complementarily is observed between the binding site and the N-terminal peptide. The disrupted aromatic cage is shown in yellow with
the inserted helix highlighted. The occluded aromatic cage is shown in the lower inset. Electrostatic surface representation is shown only for the aromatic cage with the Trp50
residue excluded.
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residues 4–69. Terminal residues were disordered and without
supporting electron density. As a result, they were omitted in this
model. Analysis of the structure using the PISA [31] server did not
indicate the presence of interfaces that might lead to homo-oligo-
merization in solution. A search of the PDB database using the
protein structure comparison service Fold at the European Bioin-
formatics Institute (http://www.ebi.ac.uk/msd-srv/ssm) showed
the domain to closely resemble other Tudor domains including
the Tud2 structure reported herein (rmsd = 1.5 Å), human SMN
protein (PDB 1MHN, rmsd = 1.32 Å), and human Tudor domain-
containing protein 3 (PDB 3PMT, rmsd = 1.68 Å) [32]. Good align-
ment was also observed with other members of the Tudor family,
including the individual Tudor domains of 53BP1 (PDB 2IG0) [33],
and JMJD2A (PDB 2QQS) [34]).
The N-terminus of Tud1 occupies a binding site opposite to the
putative aromatic cage. Binding of the N-terminal tail is stabilized
by three primary interactions (Fig. 2). Firstly, interaction between
the pyrrolidine of Pro5 and the indole of Trp60 stabilizes the far
N-terminus of the tail. Hydrogen bond interactions between the
side chain of R8 and the mainchain atoms of Trp60, Ser62 and
Leu65 serve as a second anchoring point along the tail. Finally,
hydrophobic interactions between the side chain of F13 and a
pocket formed by Ile33, Val43, Trp60, and Leu65 provide a signiﬁ-
cant surface for N-terminal stabilization. This results in a well-
ordered N-terminal tail, with the exception of residues 1–3.
PHF20-Tud1 possesses an atypical, but complete aromatic cage
comprising Asp23, Tyr29, Phe47, Trp50 and Tyr54 (Fig. 2). Compar-
ison of this site with the aromatic cages of other structurally
characterized Tudor domains reveals the backbone atoms ofTrp50 and Tyr54 to be signiﬁcantly displaced relative to equivalent
residues of other competent aromatic cages. This distortion ap-
pears to result from the presence of a 310-helix turn spanning
residues Asn51 to Asp55, which shortens strand b4 and generates
a novel Tudor domain variant. Not seen in other Tudor domains of
known structure, the he 310-helix results in occlusion of a potential
aromatic cage by the positioning of Trp50 toward the center of the
binding site, preventing recognition of methylated residues by this
domain.
3.2. Tud2 domain of PHF20 displays canonical Tudor architecture
The structure of residues 83 to 150 (PHF20-Tud2) also com-
prises a canonical Tudor domain with 5 anti-parallel b-strands.
The structure was determined by molecular replacement to 2.3 Å
resolution (Table 1, Fig. 3A). Electron density was apparent for all
residues in this expression construct. PISA analysis also failed to
identify potential dimerization interfaces amongst the crystal
contacts. Structural alignment of the Tud2 domain with other
Tudor domains reveals strong structural similarity with the afore-
mentioned Tud1 of PHF20, as well as other members of the Tudor
domain family with root mean squared deviations ranging from
1.3–1.9 Å on alignment of the backbone atoms.
The aromatic cage of PHF20-Tud2 comprises Trp97, Tyr103,
Phe120, Asp122, and Val124. Alignment of PHF20-Tud2 with other
individual Tudor domains from proteins such as 53BP1, PHF1,
PHF19, and TDRD3 reveals excellent structural conservation for
the residues comprising the aromatic cage. The alignment of this
domain with 53BP1 is presented in Fig. 3B to illustrate the conser-
vation of the methyllysine binding site (Fig. 3B). By amino acid
Fig. 3. The crystal structure of Tud2 from PHF20. (A) The canonical Tudor fold and aromatic cage (shown in yellow) of PHF20-Tud2. (B) Alignment with other Tudor domains
reveals an excellent conservation of both fold and aromatic cage. Here, we show this domain aligned with Tudor domains from SMN, PHF1 and PHF19. (C) The aromatic cage
of PHF20 is highly similar to that of Lamin B (PDB ID 2L8D). (D) The Tud2 domain exhibits intermolecular disulﬁde bonding (yellow) to form a novel Tudor domain
homodimer.
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receptor, which comprises Trp, Tyr, Tyr, Asp, and Thr52 (Fig. 3C).
Alignment of the PHF20-Tud2 domain with the NMR structures
of Lamin B (PDB 2L8D and 2DIG), however, reveals little structural
difference in the aromatic cage region, save for the rotation of
PHF20-Trp97 90 relative to the Lamin B structures. The structure
reported herein reveals dimerization of the Tud2 domain mediated
by two intermolecular disulﬁde bonds from two symmetry-related
molecules (Fig. 3D). The two disulﬁde bonds are formed between
Cys96 of molecule A and Cys100 of molecule B, and Cys100 of
molecule A and Cys96 of molecule B. The dimeric form of PHF20-
Tud2 was not apparent on size exclusion chromatography and no
additional evidence supports the formation of dimeric PHF20-
Tud2 in solution or in vivo.3.3. The tandem Tudor domains of PHF20 are highly similar to those of
PHF20L1
The tandem Tudor domains of PHF20 are highly similar to those
of the PHF20L1 protein with a large number of strictly conserved
residues evident in the sequence alignment for this region
(Fig. 4A). Comparison of PHF20-Tud1 structure with those of ﬁrst
Tudor domain of PHF20L1 (PHF20L1-Tud1) (Fig. 4B, PDBs 2JTP
and 2EQM, NMR structures) reveals a similar potential peptide
binding site, occluded by the N-terminal tail, is present in the
PHF20L1-Tud1 (Fig. 4B and C). All residues of the N-terminal tail
have been described for the 2EQM structure and the backbone
atoms of this peptide correspond well with those of PHF20-Tud1
(Fig. 4B and C). The 2EQM entry also describes an insertion of the
Fig. 4. The Tudor domains of PHF20 are highly similar to those of PHF20L1. (A) The sequence alignment of the residues 1–150, comprising the Tudor domain segments, of
PHF20 and PHF20L1. Strictly conserved residues are denoted by the asterisks and residues comprising the aromatic cages are underlined for each domain. (B) The structural
alignment of PHF20-Tud1with the NMR structures of PHF20L1-Tud1 (PDBs 2JTP and 2EQM). PHF20-Tud1 is shown in teal, 2EQM in gray and 2JTP in yellow. Four residues of
the occluded aromatic cage are indicated. (C) PHF20L1-Tud1 possesses and ordered N-terminal segment (PDB 2EQM, shown in gray) in which the F13 residue inserts into a
hydrophobic pocket. The electrostatic surface representation for binding cleft is shown. (D) A second NMR structure of the PHF20L1-Tud1 domain (PDB 2JTP) exhibits much
greater ﬂexibility that 2EQM. The left and right panels show the individual conformers of Phe13 and Tyr54, respectively, for the NMR ensemble. (E) The Tud2 domains of
PHF20 (purple) and PHF20L1 (gray) are highly similar. The residues of the aromatic cage are strictly conserved and are indicated here.
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(Fig. 4c). Support for the importance of interactions between the
proline and arginine in ordering the N-terminal peptide in this cleft
is provided by the 2JTP structure in which residues 1 to 6 have
been omitted. The N-terminal peptide of 2JTP is not ordered and
the F13 residue is no longer anchored into the hydrophobic pocket,
assuming numerous conformations in the 15 reported NMR
models (Fig. 4C and D).
All residues of the putative PHF20-Tud1 aromatic cage are
conserved in the corresponding cage of PHF20L1 and, in likewise
fashion, the potential binding pockets are occluded by insertion of
a Trp residue (Fig. 4B). However, the independent NMR structuresof this domain (PDBs 2JTP and 2EQM) reveal differences between
each other and with respect to PHF20-Tud1. Neither structure of
PHF20L1 presents a pseudo-helical insertion between residues 51
and 55 in any of the deposited NMR models (Fig. 4B). Additionally,
the position of Tyr54 differs dramatically between the two PHF20L1
structures. In 2JTP, Tyr54 is completely ﬂipped out of the pocket
and highly ﬂexible when compared amongst the models used to
generate the average deposited model (Fig. 4D). In the 2EQM struc-
ture, however, Tyr54 is structurally conserved with respect to
PHF20-Tud1 and less ﬂexibility is apparent among the structure
ensemble, supporting the PHF20-Tud2 structure of the occluded
aromatic cage.
Fig. 5. PHF20-Tud2 binds dimethylated peptides derived from the H3 and H4 histone tails. The ability of the individual Tudor domains of PHF 20 to interact with unmodiﬁed
and lysine methylated peptides derived from the H3 and H4 histone tails was assessed via ﬂuorescence polarization. Only Tud2 was show to be capable of recognizing such
peptides and exhibited a preference for peptides containing dimethylated lysine residues. (A). Binding of Tud2 to H3K9me2, H3K27me3, H3K36me2, H3K79me2 and
H4K20me2 peptides. (B)Binding of Tud2 to histone H3K4 peptides.
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domain of PHF20L1 (PHF20L1-Tud2, PDB 2EQU) reveals little
difference between the two proteins (Fig. 4E). Sequence-wise, the
aromatic cage is conserved between the two proteins (Fig. 4A).
The only apparent structural difference at the methyllysine binding
site is the rotation of the Trp97 sidechain in the PHF20L1-Tud2
structure (Fig. 4E).
3.4. Tud2 but not Tud1 binds dimethylated histone substrates
Potential interactions between the Tudor domains of PHF20 and
various histone substrates were probed using ﬂuorescence anisot-
ropy measurements with ﬂuorescence labeled ligands. Tud1 of
PHF20 failed to exhibit any interactions with the peptides screened.
Tud2 exhibited a preference for dimethylated substrates (Fig. 5A,
Supplemental Table 1). No signiﬁcant afﬁnity was measurable for
the other methylation states of this peptide, showing a clear prefer-
ence of the Tud2 pocket for dimethyllysine (Fig. 5B).
4. Discussion
.Methylation of histone tails inﬂuences overall chromatin struc-
ture and the accessibility of DNA segments. Recognition of these
methyl marks has been attributed to the Royal Family of proteins,
which includes the Tudor domain subfamily. Tudor domain-con-
taining proteins may possess one or more copies of the domain.
tandem Tudor domains (TTD), in which two individual domains
reside in very close proximity to one another, assume a wide vari-
ety of architectures (see Supplemental Fig. 1) [33–35]. The diver-
sity of TTD arrangements is likely due to the variations of
interdomain linkers, as well as the inherent ﬂexibility of the Tudor
domain itself [36]. We have divided the TTD of PHF20 into two
separate domains to improve the stability of our expression con-
structs for structural studies as the TTD was not stable in solution.
We were unable to perform structural or biochemical studies on
the TTD expression constructs. This work demonstrates that the
TTD arrangement is not essential for the stability of individual
Tudor domains in PHF20. Also consistent with other TTD-contain-
ing proteins, only one TTD (Tud2) capable of binding methylated
histone substrates.
The PHF20-Tud1 exhibited no afﬁnity for methylated peptides
in our studies. While sequence analysis suggested the presence
of putative aromatic cage, structural analysis revealed an occludedaromatic cage. The same was true for the homolog, PHF20L1-Tud1.
Both structures, however, suggested a mechanism for peptide
recognition by an extended binding site on the face opposite the
occluded aromatic cage. The interaction between the N-terminal
tail and this binding cleft is similar to that observed between the
ﬁrst pocket of L3MBTL1 and the C-terminal tail of a symmetry-
related molecule [37] where the ‘‘REPSSA’’ peptide segment forms
a type II b turn with the pyrrolidine ring residing within the hydro-
phobic pocket. Both structural features were observed in crystallo-
graphic and NMR structures, suggesting a function relevance in
both crystal and solution states.
The PHF20-Tud2 domain was shown here to have a preference
for dimethylated lysine residues. Structural comparison with
PHF20L1 suggests that the homolog is also capable of methyllysine
recognition. In contrast, he Tudor domain of Lamin B was recently
reported to not bind these modiﬁed peptides, demonstrating that
slight differences in the aromatic cages of Tudor domain family
members have signiﬁcant impact on peptide recognition [38].
The PHF20 protein has been isolated from MLL methyltransfer-
ase complexes involved in the deposition ofmethylmarks along his-
tone tails. The dimethylation of H3K4 is carried out by the SET1
family of enzymes, which comprises MLL1 through 5 and SET1A/B
[39]. Studies of the localization of H3K4me2 across the whole gen-
ome have indicated that this mark is associated with genes poised
for transcription, while the trimethylation of H3K4 is associated
with actively transcribed genes [40,41]. The ability of PHF20-Tud2
to recognize dimethylated histone substrates may be an important
contributor to the regulation and/or assembly of MLL complexes.
Following release of the crystal structures described here, addi-
tional crystal structures representing Tud1 [42] and Tud2 [43]
respectively, were also released to the public. Those models can be
aligned with rmsds of 0.47 Å (0.46 Å in case of chain B of entry
3SD4) and 0.49 Å (0.29 Å in case of chain B of entry 3P8D) against
their respective equivalents 3Q1J and 3QII, which are described
here.
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